ONTO Stock Up 126% in a Year: Is More Upside on the Horizon?

Onto Innovation reported record second-quarter revenue of $343.1 million, up 35.3% year over year, and non-GAAP EPS of $1.93 versus $1.25 a year earlier; backlog topped $1 billion. Management raised its 2026 advanced-packaging growth outlook to at least 80% from more than 50% and expects advanced-nodes revenue growth above 35%; Dragonfly orders from one OSAT exceeded $200 million, mostly for 2027 delivery. The company also agreed to buy a 27% stake in Rigaku for about $710 million. Shares have risen 125.6% over the past year, leaving valuation, customer concentration, costs and semiconductor-cycle exposure as risks.

Analysis

The key underwriting question is whether Onto’s process-control tools become an essential, repeat-purchase step as HBM and 2.5D packaging complexity rises—or remain a cyclical equipment purchase tied to a small number of buildouts. The former could support a longer earnings runway; the latter leaves the stock vulnerable to order timing and utilization pauses. The large OSAT commitment is meaningful evidence of customer adoption, but a single customer and 2027 delivery concentration make it less diversified than headline backlog implies. Track conversion into shipments, acceptance and follow-on orders, not bookings alone.

Near term, strong guidance can sustain momentum, but after a substantial rerating the stock may react asymmetrically: merely meeting elevated growth expectations could be insufficient. Over 1–3 months, quarterly revenue progression, margin delivery despite input costs, and any incremental Dragonfly orders are the catalysts. Over 6–18 months, Atlas adoption beyond initial customers and cross-selling X-ray capability through the Rigaku investment could broaden the opportunity; integration costs or delayed customer qualification could instead dilute returns.

The valuation comparison is not simply “ONTO is expensive”: the article’s cited forward multiple is below those of the three named equipment peers. That does not make it cheap in absolute terms, but it weakens a peer-relative short thesis. The more relevant discount risks are customer concentration, execution and whether packaging growth persists beyond the current AI investment wave. KLA, Camtek and Nova may also benefit from expanding process-control budgets; treat them as imperfect hedges, not clean losers.

Key Decisions for Investors

• Do not chase a momentum extension solely on bookings. Consider a staged ONTO long on broad equipment-sector weakness or a post-results pullback, with position size reflecting customer concentration and the sharp prior rerating; there is no price-level information here to set a precise entry.
• For the next 1–3 months, monitor quarterly revenue against guidance, gross/operating margin delivery, and Dragonfly orders converting into shipments and customer acceptance. Upside case: continued sequential growth and margin expansion; downside case: bookings remain strong but revenue conversion or margins disappoint.
• Treat the Rigaku stake as a 6–18 month strategic option, not near-term earnings proof. Verify purchase funding, integration costs, and evidence that X-ray capability generates incremental customer wins rather than overlapping existing tools.
• Falsify the bullish thesis if management cuts advanced-packaging or advanced-node outlook, the major OSAT order fails to convert on schedule, margins contract despite revenue growth, or customer spending weakens across Taiwan and South Korea. A broad AI-capex slowdown would pressure ONTO and its equipment peers, so peer shorts are unlikely to provide a clean hedge.